Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study-Reference-Cited by-同舟云学术

Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Published:2020-12 Issue:6 Volume:18 Page:461-468.e3
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Vogelzang Nicholas J.,Olsen Mark R.,McFarlane Joshua J.,Arrowsmith Edward,Bauer Todd M.,Jain Rohit K.,Somer Bradley,Lam Elaine T.,Kochenderfer Mark D.,Molina Ana,Doshi Gurjyot,Lingerfelt Brian,Hauke Ralph J.,Gunuganti Vijay,Schnadig Ian,Van Veldhuizen Peter,Fleming Mark,Galamaga Robert,Gupta Mukul,Hool Hugo,Hutson Thomas,Zhang Joshua,McHenry M. Brent,Johansen Jennifer L.,Tykodi Scott S.

Funder

Bristol-Myers Squibb Company

BMS

Daiichi-Sankyo

Medpacto

Incyte

Mirati Therapeutics

MedImmune

AbbVie

AstraZeneca

MabVax

Stemline Therapeutics

Merck

Lilly

GlaxoSmithKline

Novartis

Genentech

Deciphera

Merrimack

Immunogen

Millennium

Phosplatin Therapeutics

Calithera Biosciences

Kolltan Pharmaceuticals

Principa Biopharma

Peleton

Immunocore

Roche

Aileron Therapeutics

Amgen

Onyx

Sanofi

Boehringer-Ingelheim

Astellas Pharma

Five Prime Therapeutics

Jacobio

Top Alliance BioScience

Janssen

Clovis Oncology

Takeda

Karyopharm Therapeutics

Foundation Medicine

ARMO Biosciences

Leap Therapeutics

Ignyta

Moderna Therapeutics

Pfizer

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference15 articles.

1. Review of renal cell carcinoma and its common subtypes in radiology;Low;World J Radiol,2016

2. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis;Vera-Badillo;Eur Urol,2015

3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

4. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial;Cella;Lancet Oncol,2016

5. OPDIVO (nivolumab),2020

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy;Japanese Journal of Clinical Oncology;2024-08-23

2. Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial;European Urology;2024-08

3. Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC;Cancers;2024-06-20

4. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances;American Society of Clinical Oncology Educational Book;2024-06

5. The role of immunotherapy in urological cancers;Archivio Italiano di Urologia e Andrologia;2024-05-30